Insider Buying: BioRestorative Therapies, Inc. (NASDAQ:BRTX) Major Shareholder Buys 36,374 Shares of Stock

BioRestorative Therapies, Inc. (NASDAQ:BRTXGet Free Report) major shareholder Dale Broadrick purchased 36,374 shares of the stock in a transaction dated Wednesday, February 7th. The shares were acquired at an average price of $1.38 per share, for a total transaction of $50,196.12. Following the acquisition, the insider now directly owns 363,419 shares of the company’s stock, valued at approximately $501,518.22. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Major shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Dale Broadrick also recently made the following trade(s):

  • On Friday, December 1st, Dale Broadrick sold 250 shares of BioRestorative Therapies stock. The shares were sold at an average price of $1.88, for a total value of $470.00.
  • On Monday, November 27th, Dale Broadrick sold 278 shares of BioRestorative Therapies stock. The shares were sold at an average price of $1.89, for a total value of $525.42.

BioRestorative Therapies Trading Up 5.5 %

Shares of BRTX stock opened at $1.35 on Friday. BioRestorative Therapies, Inc. has a 1-year low of $1.20 and a 1-year high of $7.13. The company’s fifty day simple moving average is $1.77.

BioRestorative Therapies (NASDAQ:BRTXGet Free Report) last issued its quarterly earnings results on Monday, November 13th. The company reported ($0.64) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.68) by $0.04. The business had revenue of $0.03 million for the quarter, compared to the consensus estimate of $0.03 million. BioRestorative Therapies had a negative return on equity of 117.00% and a negative net margin of 12,195.10%. On average, equities research analysts anticipate that BioRestorative Therapies, Inc. will post -3.52 EPS for the current year.

Institutional Trading of BioRestorative Therapies

Institutional investors have recently bought and sold shares of the company. Lynwood Capital Management Inc. acquired a new stake in BioRestorative Therapies during the third quarter valued at $36,000. FNY Investment Advisers LLC acquired a new stake in BioRestorative Therapies during the third quarter valued at $26,000. Finally, Vanguard Group Inc. boosted its position in BioRestorative Therapies by 8.6% during the third quarter. Vanguard Group Inc. now owns 137,818 shares of the company’s stock valued at $247,000 after purchasing an additional 10,862 shares during the last quarter. Institutional investors and hedge funds own 6.93% of the company’s stock.

BioRestorative Therapies Company Profile

(Get Free Report)

BioRestorative Therapies, Inc, a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders.

Further Reading

Insider Buying and Selling by Quarter for BioRestorative Therapies (NASDAQ:BRTX)

Receive News & Ratings for BioRestorative Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioRestorative Therapies and related companies with MarketBeat.com's FREE daily email newsletter.